Press release from Companies
Publicerat: 2020-10-08 08:20:00
Today is the first day of trading in Curasight A/S ("Curasight") shares and warrants of series TO 1. Curasight’s shares are traded under the ticker "CURAS" with ISIN DK0061295797 and Curasight’s warrants of series TO 1 are traded under the ticker "CURAS TO 1" with ISIN DK0061408747.
Ahead of the listing at Spotlight Stock Market, Curasight has conducted a successful IPO which has provided the company with approx. DKK 32.7 million (before issue costs) and approx. 1,700 new shareholders. The issue funds will primarily finance the completion of a therapeutic preclinical study in brain cancer and a clinical phase III image study in brain cancer with the objective to obtain FDA approval and commercialize the uTRACE® platform. The total number of shares in Curasight is 17,126,340 shares and the share capital amounts to DKK 856,317.00. In addition, there are a total of 2,835,000 warrants of series TO 1 issued. Each warrant of series TO 1 entitles the holder the right to subscribe for one (1) new share in Curasight at a subscription price of DKK 17.20 per share during the exercise period September 16, 2021 until October 7, 2021. Financial advisor and legal advisor Sedermera Fondkommission is the financial advisor of Curasight in connection with the capitalization and listing. Markets & Corporate Law is the legal advisor. For additional information regarding the capitalization, please contact: Sedermera Fondkommission Phone: +46 (0) 40-615 14 10 E-mail: info@sedermera.se For more information regarding Curasight, please contact: Ulrich Krasilnikoff, CEO Phone: +45 22 83 01 60 E-mail: uk@curasight.com Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology provides improved diagnosis and risk stratification in multiple cancer types.
